Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults (vol 36, pg 6325, 2018)

被引：0

作者：

Brandon, Donald ^{[1
]}

Kimmel, Murray ^{[2
]}

Kuriyakose, Sherine O. ^{[3
]}

Kostanyan, Lusine ^{[4
,5
]}

Mesaros, Narcisa ^{[5
]}

机构：

[1] Calif Res Fdn, 4180 Ruffin Rd, San Diego, CA 92123 USA

[2] Accelovance Suite, Suite 102,1600 West Eau Gallie Blvd, Melbourne, FL USA

[3] GSK, 5 Embassy Links,Cunningham Rd, Bangalore 560052, Karnataka, India

[4] XPE Pharma & Sci, 19A Ave Edison, B-1300 Wavre, Belgium

[5] GSK, 20 Ave Fleming, B-1300 Wavre, Belgium

来源：

VACCINE | 2020年 / 38卷 / 12期

关键词：

D O I：

10.1016/j.vaccine.2020.01.082

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2746 / 2747

页数：2

共 38 条

[21] Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life:: Safety, immunogenicity and persistence of antibody responses
Heininger, U.
Saenger, R.
Jacquet, J. M.
Schuerman, L.
VACCINE, 2007, 25 (06) : 1055 - 1063
[22] Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose
Halperin, Scott A.
McNeil, Shelly
Langley, Joanne
Blatter, Mark
Dionne, Marc
Embree, Joanne
Johnson, Roehl
Latiolais, Thomas
Meekison, William
Noya, Francisco
Senders, Shelly
Zickler, Paul
Johnson, David R.
VACCINE, 2011, 29 (46) : 8459 - 8465
[23] Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women
Sompagdee, Nalat
Anuwutnavin, Sanitra
Phongsamart, Wanatpreeya
Senawong, Sansnee
Umrod, Pinklow
Robkhonburi, Amporn
VACCINE, 2020, 38 (12) : 2725 - 2733
[24] Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV, Repevax®) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip®) to adults aged ≥60 years: An open-label, randomised trial
Zimmermann, Ulrich
Gavazzi, Gaetan
Richard, Patrick
Eymin, Cecile
Soubeyrand, Benoit
Baudin, Martine
VACCINE, 2013, 31 (11) : 1496 - 1502
[25] Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years
Dominicus, Rolf
Gaiter, Florence
Richard, Patrick
Saudin, Martine
VACCINE, 2014, 32 (31) : 3942 - 3949
[26] Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age
Langue, J
Matisse, N
Pacoret, P
Undreiner, F
Boisnard, F
Soubeyrand, B
VACCINE, 2004, 22 (11-12) : 1406 - 1414
[27] Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®)A Review of its Use as a Single-Dose Booster Immunization in Individuals Aged 10–64 Years in the US
Greg L. Plosker
BioDrugs, 2009, 23 : 253 - 267
[28] Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®) A Review of its Use as a Single-Dose Booster Immunization in Individuals Aged 10-64 Years in the US
Plosker, Greg L.
BIODRUGS, 2009, 23 (04) : 253 - 267
[29] Immunogenicity, Safety, and Antibody Persistence at 3, 5, and 10 Years Postvaccination in Adolescents Randomized to Booster Immunization with a Combined Tetanus, Diphtheria, 5-Component Acellular Pertussis, and Inactivated Poliomyelitis Vaccine Administered with a Hepatitis B Virus Vaccine Concurrently or 1 Month Apart
Embree, Joanne
Law, Barbara
Voloshen, Tim
Tomovici, Antigona
CLINICAL AND VACCINE IMMUNOLOGY, 2015, 22 (03) : 282 - 290
[30] Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children
Gatchalian, Salvacion R.
Ramakrishnan, Gunasekaran
Bock, Hans L.
Lefevre, Inge
Jacquet, Jeanne M.
HUMAN VACCINES, 2010, 6 (08): : 664 - 672

← 1 2 3 4 →